You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Express Scripts
McKesson
Moodys
AstraZeneca

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Tasquinimod


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Tasquinimod?

Tasquinimod is an investigational drug.

There have been 10 clinical trials for Tasquinimod. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Carcinoma, and Stomach Neoplasms. The leading clinical trial sponsors are Active Biotech AB, Ipsen, and Roswell Park Cancer Institute.

There are eleven US patents protecting this investigational drug and one hundred and four international patents.

Recent Clinical Trials for Tasquinimod
TitleSponsorPhase
Tasquinimod for the Treatment of Relapsed or Refractory MyelomaActive Biotech ABPhase 1
Tasquinimod for the Treatment of Relapsed or Refractory MyelomaUniversity of PennsylvaniaPhase 1
A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate CancerSidney Kimmel Comprehensive Cancer CenterPhase 1

See all Tasquinimod clinical trials

Clinical Trial Summary for Tasquinimod

Top disease conditions for Tasquinimod
Top clinical trial sponsors for Tasquinimod

See all Tasquinimod clinical trials

US Patents for Tasquinimod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tasquinimod   Start Trial Quinoline carboxamides for use in the treatment of leukemia ACTIVE BIOTECH AB (Lund, SE)   Start Trial
Tasquinimod   Start Trial Quinoline carboxamides for use in the treatment of multiple myeloma Active Biotech AB (Lund, SE)   Start Trial
Tasquinimod   Start Trial Quinoline derivatives Active Biotech AB (Lund, SE)   Start Trial
Tasquinimod   Start Trial Drugs for the treatment of malignant tumors Active Biotech AB (Lund, SE)   Start Trial
Tasquinimod   Start Trial Quinoline derivatives Active Biotech AB (Lund, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tasquinimod

Drugname Country Document Number Estimated Expiration Related US Patent
Tasquinimod Australia 2015348778 2034-11-19   Start Trial
Tasquinimod Brazil 112017009854 2034-11-19   Start Trial
Tasquinimod Canada 2967112 2034-11-19   Start Trial
Tasquinimod China 107072989 2034-11-19   Start Trial
Tasquinimod Eurasian Patent Organization 031643 2034-11-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Colorcon
McKesson
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.